SAMPLE QUALITATIVE PRESS RELEASE LANGUAGE

For Immediate Release **Contact:** **Helen Smith**
[DATE] 213-999-9999

Acme Pharmaceuticals Announces That Phase III Trial of Compound X for Advanced Liver Cancer Met Primary Endpoint

QUALITATIVE: *Los Angeles, Calif.*—Acme Pharmaceuticals (NYSE: ACM) announced today that its Phase III clinical trial of Compound X met its primary endpoint of improved overall survival for patients with advanced liver cancer, when compared with patients receiving a placebo. Further results will be presented at the [YEAR] American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June [DATE]. *(vs. QUANTITATIVE: Acme Pharmaceuticals (NYSE: ACM) announced today that its Phase III clinical trial of Compound X met its primary endpoint of improved overall survival for patients with advanced liver cancer, when compared with patients receiving a placebo. In the trial, 342 patients were randomized to either the treatment arm, receiving 15 mg. of Compound X every three weeks, or the placebo arm. Overall survival for the treatment arm was 64%, compared with 41% for the placebo arm.)*

QUALITATIVE: "Acme is pleased to report that Compound X has shown significant results in the treatment of this historically hard-to-treat cancer," said John Jones, MD, Acme's chief executive officer. "We are deeply appreciative of the cancer patients and clinical investigators and who participated in this trial and look forward to presenting the results at the ASCO Annual Meeting." *(vs. QUANTITATIVE: "Acme is thrilled to report that Compound X has shown significant results in the treatment of this historically hard-to-treat cancer," said John Jones, MD, Acme's chief executive officer. "The statistically significant 25% difference in overall survival between the treatment and placebo arms is promising news for patients and will likely change the standard of care.")*

About the Compound X Trial

QUALITATIVE: In this multi-national, Phase III, randomized, placebo-controlled trial, more than 300 patients with advanced hepatocellular carcinoma (HCC) who had no prior therapy were randomized to receive either Compound X or a placebo. The trial's objective was to determine

improved overall survival between the Compound X and placebo arms. *(vs. QUANTITATIVE: In the trial, 342 patients were randomized to either the treatment arm, receiving 15 mg. of Compound X every three weeks, or the placebo arm. Overall survival for the treatment arm was 64%, compared with 41% for the placebo arm. There were no significant differences in the side effects profile between the treatment and placebo arms. The most serious side effects were diarrhea, fatigue, and alopecia.)*

About Acme Pharmaceuticals

[company boilerplate]

Forward Looking Statements

[company boilerplate]